This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (funded, already peer-reviewed, non-eHealth) (172)

Published on in Vol 9, No 4 (2020): April

Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial

Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial

Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial

Authors of this article:

Shinobu Shimizu1 Author Orcid Image ;   Masahiro Iijima1, 2 Author Orcid Image ;   Yuki Fukami2 Author Orcid Image ;   Natsuko Tamura1, 3 Author Orcid Image ;   Masahiro Nakatochi1, 4 Author Orcid Image ;   Masahiko Ando1 Author Orcid Image ;   Ryoji Nishi2 Author Orcid Image ;   Haruki Koike2 Author Orcid Image ;   Kenichi Kaida5 Author Orcid Image ;   Michiaki Koga6 Author Orcid Image ;   Takashi Kanda6 Author Orcid Image ;   Hidenori Ogata7 Author Orcid Image ;   Jun-Ichi Kira7 Author Orcid Image ;   Masahiro Mori8 Author Orcid Image ;   Satoshi Kuwabara8 Author Orcid Image ;   Masahisa Katsuno2 Author Orcid Image
Article Authors Cited by (26) Tweetations (2) Metrics

Journals

  1. Koike H, Katsuno M. Pathophysiology of Chronic Inflammatory Demyelinating Polyneuropathy: Insights into Classification and Therapeutic Strategy. Neurology and Therapy 2020;9(2):213 View
  2. Rajabally Y, Goedee H, Attarian S, Hartung H. Management challenges for chronic dysimmune neuropathies during the COVID‐19 pandemic. Muscle & Nerve 2020;62(1):34 View
  3. Sahi N, Ghasemi M, Rajabally Y. Autoantibodies in the diagnostic work-up of neuropathy: clinically useful or purely academic?. British Journal of Hospital Medicine 2020;81(7):1 View
  4. Iijima M. Treatment of chronic inflammatory demyelinating polyradiculoneuropathy patients with antibodies against paranodal proteins. Clinical and Experimental Neuroimmunology 2020;11(2):94 View
  5. Fukami Y, Iijima M, Koike H, Yamada S, Hashizume A, Katsuno M. Association of serum neurofilament light chain levels with clinicopathology of chronic inflammatory demyelinating polyneuropathy, including NF155 reactive patients. Journal of Neurology 2021;268(10):3835 View
  6. Koike H, Katsuno M. The role of macrophages in Guillain‐Barré syndrome and chronic inflammatory demyelinating polyneuropathy. Neurology and Clinical Neuroscience 2021;9(3):203 View
  7. Menon D, Katzberg H, Bril V. Treatment Approaches for Atypical CIDP. Frontiers in Neurology 2021;12 View
  8. Hu J, Sun C, Lu J, Zhao C, Lin J. Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. Journal of Neurology 2022;269(3):1250 View
  9. Kira J. Anti-Neurofascin 155 Antibody-Positive Chronic Inflammatory Demyelinating Polyneuropathy/Combined Central and Peripheral Demyelination: Strategies for Diagnosis and Treatment Based on the Disease Mechanism. Frontiers in Neurology 2021;12 View
  10. Sahi N, Ghasemi M, Rajabally Y. Autoantibodies in the diagnostic work-up of neuropathy: clinically useful or purely academic?. British Journal of Neuroscience Nursing 2021;17(3):84 View
  11. Sokmen O, Demirci M, Tan E. A case with Neurofascin-155 IgG antibody-associated combined central and peripheral demyelination: Successfully treated with anti-CD20 monoclonal antibody. Clinical Neurology and Neurosurgery 2021;210:106961 View
  12. Hu J, Zhao C, Lin J. Potential therapeutic strategies in chronic inflammatory demyelinating polyradiculoneuropathy. Autoimmunity Reviews 2022;21(4):103032 View
  13. Briani C, Visentin A. Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies. Neurotherapeutics 2022;19(3):874 View
  14. Sivadasan A, Bril V. Therapies in Autoimmune Peripheral Neuropathies beyond Intravenous Immunoglobulin, Plasma Exchange and Corticosteroids: An Analytical Review. Transfusion Medicine Reviews 2022;36(4):220 View
  15. Querol L, Lleixà C. Novel Immunological and Therapeutic Insights in Guillain-Barré Syndrome and CIDP. Neurotherapeutics 2021;18(4):2222 View
  16. Appeltshauser L, Junghof H, Messinger J, Linke J, Haarmann A, Ayzenberg I, Baka P, Dorst J, Fisse A, Grüter T, Hauschildt V, Jörk A, Leypoldt F, Mäurer M, Meinl E, Michels S, Motte J, Pitarokoili K, Stettner M, Villmann C, Weihrauch M, Welte G, Zerr I, Heinze K, Sommer C, Doppler K. Anti-pan-neurofascin antibodies induce subclass-related complement activation and nodo-paranodal damage. Brain 2023;146(5):1932 View
  17. Svačina M, Lehmann H. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Current Therapies and Future Approaches. Current Pharmaceutical Design 2022;28(11):854 View
  18. Fatehi F, Okhovat A, Panahi A, Ziaaddini B, Rajabally Y, Nafissi S. Retrospective analysis of response to rituximab in chronic inflammatory demyelinating polyneuropathy refractory to first‐line therapy. Journal of the Peripheral Nervous System 2021;26(4):469 View
  19. Chaganti S, Hannaford A, Vucic S. Rituximab in chronic immune mediated neuropathies: a systematic review. Neuromuscular Disorders 2022;32(8):621 View
  20. Ogata H. The significance of autoantibodies against nodal and paranodal proteins in autoimmune nodopathies. Rinsho Shinkeigaku 2023;63(11):715 View
  21. Dziadkowiak E, Nowakowska-Kotas M, Rałowska-Gmoch W, Budrewicz S, Koszewicz M. Molecular, Electrophysiological, and Ultrasonographic Differences in Selected Immune-Mediated Neuropathies with Therapeutic Implications. International Journal of Molecular Sciences 2023;24(11):9180 View
  22. Kuwahara M. Prospect of novel therapies in immune-mediated neuropathies. Rinsho Shinkeigaku 2024;64(1):1 View
  23. Zheng Y, Hu J, Sun C, Qiao K, Zhao Y, Liu B, Sun J, Xi J, Luo S, Lu J, Zhao C, Lin J. Insights into refractory chronic inflammatory demyelinating polyneuropathy: a comprehensive real-world study. Frontiers in Neurology 2024;15 View
  24. Min Y, Shin H, Sung J. Autoimmune Nodopathy: When to Suspect and How to Treat?. Journal of Multiple Sclerosis and Neuroimmunology 2024;15(1):23 View
  25. Mair D, Madi H, Eftimov F, Lunn M, Keddie S. Novel therapies in CIDP. Journal of Neurology, Neurosurgery & Psychiatry 2024:jnnp-2024-334165 View

Books/Policy Documents

  1. Antonelli E, Palmeri D, Apricena A, Danieli M. Regulatory T Cells and Autoimmune Diseases. View